Bulletin
Investor Alert

New York Markets Open in:

March 4, 2021, 8:02 a.m. EST

The Pandemic is a Long-Term Factor (US: QDEL) (nyseamerican:APT) (US: BNOW)(US: ABT)

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Quidel Corp. (QDEL)
  • X
    Boon Industries Inc. (BNOW)
  • X
    Abbott Laboratories (ABT)

or Cancel Already have a watchlist? Log In

Boon Industries (otcmkts:BNOW) is a more speculative name on this list. But shares have been performing well, rising as much as 400% since December in a steady upward trend that has also been consolidating. A move above $0.40 could be an important technical catalyst for more upside potential.

Abbott Laboratories /zigman2/quotes/203724446/composite ABT -0.46% is basically the best-of-breed for Covid-19 testing technology. The company discovers, develops, manufactures, and sells health care products worldwide.

The company's Diagnostic Products segment offers laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems; molecular point-of-care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. It also has nutrition and pharmaceutical divisions.

Abbott Laboratories /zigman2/quotes/203724446/composite ABT -0.46% recently announced that Health Canada, under interim order, authorized the expanded use of the FreeStyle Libre flash glucose monitoring system in hospital and professional health care settings to include Canadian women who are pregnant.

"The COVID-19 pandemic has presented a new set of challenges for pregnant women who are at higher risk of contracting the virus," said Nazli Topors, Pharm.D., medical director of Abbott's diabetes care business in Canada. "The expanded indication for FreeStyle Libre demonstrates the technology's positive impact on managing diabetes and the ability for health care workers to support patients during such an important time in their lives and, at the same time, limit their COVID-19 exposure while they are in the hospital."

While this is a clear factor, it has been incorporated into a trading tape characterized by a pretty dominant offer, which hasn't been the type of action ABT shareholders really want to see. In total, over the past five days, shares of the stock have dropped by roughly -3% on above average trading volume. All in all, not a particularly friendly tape, but one that may ultimately present some new opportunities.

Abbott Laboratories /zigman2/quotes/203724446/composite ABT -0.46% generated sales of $10.7B, according to information released in the company's most recent quarterly financial report. That adds up to a sequential quarter-over-quarter growth rate of 20.9% on the top line. In addition, the company is battling some balance sheet hurdles, with cash levels struggling to keep up with current liabilities ($7.1B against $11.9B, respectively).

DISCLAIMER: EDM Media LLC (EDM), is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. EDM is NOT affiliated in any manner with any company mentioned herein. EDM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. EDM's market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. EDM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed EDM has been compensated ten thousand dollars for news coverage of the current press releases issued by Boon Industries by a third party.

EDM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.

This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and EDM undertakes no obligation to update such statements.

Media Contact:

EDM Media LLC

Email: IR@EDM.Media

Office: 800-301-7883

EDM.Media

COMTEX_382129952/2632/2021-03-04T08:02:23

Is there a problem with this press release? Contact the source provider Comtex at editorial@comtex.com. You can also contact MarketWatch Customer Service via our Customer Center.

/zigman2/quotes/203724446/composite
US : U.S.: NYSE
$ 118.39
-0.55 -0.46%
Volume: 5.52M
May 11, 2021 4:02p
P/E Ratio
37.06
Dividend Yield
1.52%
Market Cap
$210.71 billion
Rev. per Employee
$317,505
loading...
/zigman2/quotes/203724446/composite
US : U.S.: NYSE
$ 118.39
-0.55 -0.46%
Volume: 5.52M
May 11, 2021 4:02p
P/E Ratio
37.06
Dividend Yield
1.52%
Market Cap
$210.71 billion
Rev. per Employee
$317,505
loading...
/zigman2/quotes/203724446/composite
US : U.S.: NYSE
$ 118.39
-0.55 -0.46%
Volume: 5.52M
May 11, 2021 4:02p
P/E Ratio
37.06
Dividend Yield
1.52%
Market Cap
$210.71 billion
Rev. per Employee
$317,505
loading...

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.